Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Duncan R McKenzie; Miguel Muñoz-Ruiz; Leticia Monin; Thanussuyah Alaguthurai; Thomas Lechmere; Sultan Abdul-Jawad; Carl Graham; Emily Pollock; Rosalind Graham; Kamila Sychowska; Jeffrey Seow; Catherine Tremain; Charalampos Gousis; Clara Domingo-Vila; Jack Cooper; Jennifer Vidler; Kasia Owczarczyk; Angela Swampillai; Hartmut Kristeleit; Michael H Malim; Paul Fields; Piers E M Patten; Sophie Papa; Bernard V North; Timothy Tree; Katie J Doores; Adrian C Hayday; Sheeba Irshad

doi:10.1016/j.ccell.2021.10.003

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12.

Authors

Duncan R McKenzie¹, Miguel Muñoz-Ruiz¹, Leticia Monin¹, Thanussuyah Alaguthurai², Thomas Lechmere³, Sultan Abdul-Jawad⁴, Carl Graham³, Emily Pollock⁵, Rosalind Graham⁴, Kamila Sychowska⁵, Jeffrey Seow³, Catherine Tremain⁶, Charalampos Gousis⁶, Clara Domingo-Vila⁵, Jack Cooper⁶, Jennifer Vidler⁷, Kasia Owczarczyk⁶, Angela Swampillai⁸, Hartmut Kristeleit⁶, Michael H Malim³, Paul Fields⁹, Piers E M Patten¹⁰, Sophie Papa⁹, Bernard V North¹¹, Timothy Tree⁵, Katie J Doores³, Adrian C Hayday¹², Sheeba Irshad¹³

Affiliations

¹ The Francis Crick Institute, London, UK.
² Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King's College London, London, UK.
³ Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, UK.
⁴ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK.
⁵ Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
⁶ Guy's and St. Thomas' NHS Foundation Trust, London, UK.
⁷ Department of Haematological Medicine, King's College Hospital, London, UK.
⁸ Breast Cancer Now Research Unit, King's College London, London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
⁹ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
¹⁰ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Department of Haematological Medicine, King's College Hospital, London, UK.
¹¹ Clinical Trials Unit, King's College London, UK.
¹² The Francis Crick Institute, London, UK; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
¹³ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King's College London, London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK; Cancer Research UK (CRUK) Clinician Scientist, London, UK. Electronic address: sheeba.irshad@kcl.ac.uk.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral / blood
BNT162 Vaccine
COVID-19 / diagnosis
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / administration & dosage*
Case-Control Studies
Cytokines / blood
Host-Pathogen Interactions
Humans
Immunity, Cellular / drug effects*
Immunity, Humoral / drug effects*
Immunization Schedule*
Immunogenicity, Vaccine*
Immunoglobulin G / blood
Neoplasms / immunology*
SARS-CoV-2 / drug effects*
SARS-CoV-2 / immunology
SARS-CoV-2 / pathogenicity
Spike Glycoprotein, Coronavirus / immunology*
T-Lymphocytes / drug effects
T-Lymphocytes / immunology
T-Lymphocytes / virology
Time Factors
Treatment Outcome
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines
Cytokines
Immunoglobulin G
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
BNT162 Vaccine

Publication types

MeSH terms

Substances

Grants and funding